Imitrexsumatriptan

According to the FDA label: IMITREX tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with IMITREX, reconsider the diagnosis of migraine before IMITREX is administered to treat any subsequent attacks. • IMITREX is not indicated for the prevention of migraine attacks.

37,201 adverse event reports submitted to the FDA (1996–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Imitrex in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Imitrex adverse event reports by reporter sex
SexReports
Female28,957
Male5,074
Unknown178

By Age Group

View age group data as a table
Imitrex adverse event reports by reporter age group
Age groupReports
0-17613
18-343,990
35-497,020
50-647,542
65-742,345
75+635

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Imitrex. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Imitrex adverse event reports by reported outcome
OutcomeReports
Non-Serious18,652
Other Serious13,487
Hospitalization6,944
Disability1,111
Life-Threatening939
Death881

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Imitrex. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Imitrex adverse event reports by year
YearReports
19962
20031
2004893
20051,256
2006842
2007851
2008792
2009865
2010797
2011904
20121,154
20131,087
20141,410
20152,197
20162,977
20172,171
20182,643
20193,028
20202,670
20212,163
20222,176
20232,170
20241,884
20251,835
2026 (partial)433

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Imitrex

In FDA adverse event reports that mention Imitrex, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026